Free Trial

LPL Financial LLC Has $10.96 Million Stock Position in Natera, Inc. (NASDAQ:NTRA)

Natera logo with Medical background

Key Points

  • LPL Financial LLC reduced its holdings in Natera, Inc. by 3.6%, now owning 77,478 shares valued at approximately $10.96 million.
  • Brokerages have responded positively, with Barclays and Royal Bank Of Canada raising their target prices for Natera, reflecting a strong buy sentiment among analysts.
  • Natera recently posted quarterly earnings of ($0.74) per share, missing estimates but achieved revenue of $546.6 million, exceeding expectations by over 14%.
  • Need Better Tools to Track Natera? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

LPL Financial LLC reduced its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 3.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 77,478 shares of the medical research company's stock after selling 2,854 shares during the period. LPL Financial LLC owned 0.06% of Natera worth $10,956,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Price T Rowe Associates Inc. MD grew its position in shares of Natera by 134.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock worth $1,067,327,000 after buying an additional 3,871,862 shares in the last quarter. SG Americas Securities LLC grew its position in shares of Natera by 8,233.5% during the first quarter. SG Americas Securities LLC now owns 397,924 shares of the medical research company's stock worth $56,270,000 after buying an additional 393,149 shares in the last quarter. Ninety One UK Ltd acquired a new stake in shares of Natera during the first quarter worth approximately $31,959,000. BNP Paribas Financial Markets boosted its holdings in Natera by 1,126.1% in the fourth quarter. BNP Paribas Financial Markets now owns 233,890 shares of the medical research company's stock worth $37,025,000 after purchasing an additional 214,814 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. boosted its holdings in Natera by 26.3% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 935,768 shares of the medical research company's stock worth $132,327,000 after purchasing an additional 194,931 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Gail Boxer Marcus sold 4,299 shares of Natera stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $167.36, for a total transaction of $719,480.64. Following the completion of the sale, the director directly owned 8,118 shares of the company's stock, valued at approximately $1,358,628.48. This trade represents a 34.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Steven Leonard Chapman sold 6,111 shares of Natera stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $157.10, for a total value of $960,038.10. Following the completion of the transaction, the chief executive officer directly owned 179,071 shares of the company's stock, valued at $28,132,054.10. This represents a 3.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 60,239 shares of company stock valued at $8,986,542. 5.63% of the stock is owned by insiders.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of recent analyst reports. Barclays restated an "overweight" rating and set a $210.00 price objective (up from $190.00) on shares of Natera in a research note on Friday. Wall Street Zen cut shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. Evercore ISI upgraded shares of Natera to a "strong-buy" rating and set a $170.00 price objective on the stock in a research note on Monday, July 28th. Royal Bank Of Canada lifted their target price on Natera from $251.00 to $255.00 and gave the stock an "outperform" rating in a report on Friday. Finally, Piper Sandler lifted their target price on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Thursday, May 15th. One analyst has rated the stock with a sell rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $192.53.

View Our Latest Stock Analysis on NTRA

Natera Trading Up 7.7%

Shares of NASDAQ NTRA traded up $10.87 during mid-day trading on Friday, reaching $151.95. 3,849,518 shares of the company's stock were exchanged, compared to its average volume of 1,668,416. The firm has a market capitalization of $20.75 billion, a price-to-earnings ratio of -79.55 and a beta of 1.76. The business has a fifty day simple moving average of $155.60 and a 200 day simple moving average of $154.85. Natera, Inc. has a twelve month low of $104.00 and a twelve month high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The firm had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative return on equity of 22.93% and a negative net margin of 12.89%. The firm's quarterly revenue was up 32.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.30) earnings per share. Equities research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Profile

(Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Featured Stories

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Should You Invest $1,000 in Natera Right Now?

Before you consider Natera, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.

While Natera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines